Designated by one office. Approved by another.

A device that might qualify as a Humanitarian Use Device has two FDA decisions ahead of it, not one, made by two different parts of the agency on two different clocks — and the earlier decision is the one no monitoring pipeline, including this one, ever sees happen.

The office before the review

Humanitarian Use Device (HUD) designation and Humanitarian Device Exemption (HDE) approval sound like two names for one process. They are not. 21 CFR Part 814, Subpart H, runs them as a sequence: a sponsor first requests HUD designation from FDA’s Office of Orphan Products Development (OOPD) — the same office that runs the orphan-drug designation program, not CDRH’s device-review staff — and only after that designation is granted can the sponsor file the HDE application itself, which CDRH reviews as a separate, later submission.

The threshold that makes a device eligible to ask is a population count: a disease or condition affecting not more than 8,000 individuals in the United States per year. That number is itself the product of an earlier statutory decision — the 21st Century Cures Act raised it from 4,000 in December 2016, and FDA’s technical amendment implementing the change took effect June 7, 2017. A device serving 9,000 patients a year and one serving 7,000 sit on opposite sides of a line Congress drew, not FDA.

A determination on a stated clock

What OOPD does with a designation request is not discretionary about timing. Per 21 CFR 814.104, FDA has 45 days from receipt to act: approve the request as submitted, or return it, pending more information, if it does not on its face contain what 21 CFR 814.102 requires. Forty-five days is a real administrative deadline. It is simply not one that runs through the Federal Register. Nothing about a HUD designation request or FDA’s answer to it triggers a Federal Register notice, a docket, or a comment period — it is a direct determination between a sponsor and an FDA office, decided and communicated without ever becoming a public document the way a classification order or a guidance notice does.

The designation is a real FDA decision, dated and clocked. It is also, on its own, invisible.

Where the fact eventually surfaces — if it does

A granted HUD designation does not populate openFDA, and it does not appear in FDA’s public HDE approvals database, because that database tracks a different, later event: an H number is assigned only once CDRH approves the HDE application the designation made possible. A sponsor can hold a valid HUD designation for months, pursuing the HDE application, a clinical strategy, or nothing at all, and the public record shows none of it. If the HDE is approved, the device surfaces there, keyed to that later date, under CDRH’s process, not OOPD’s. If it is never filed, or never approved, the designation that made it eligible stays exactly where it always was: known to FDA and the sponsor, and to no one else.

For a portfolio watch, the practical read is narrow but specific: a competitor working a small-population indication can have already cleared the harder of the two gates — designation — well before anything public suggests they are close to a marketed device. Silence from FDA’s HDE database is not evidence that no designation exists; it is evidence only that no HDE has been approved yet, which is a narrower claim. This is regulatory intelligence and method, describing where the record does and doesn’t reach — never regulatory advice about any specific sponsor’s program or timeline.

None of FDA Radar’s four sources — Federal Register, warning letters, 510(k) clearances, recall enforcement — reads an OOPD designation, and none of them ever will, because the designation step was never a document any of the four publishes. What we can read, and do, is what happens downstream of it in the sources we already watch — a recall or a warning letter against a firm pursuing the same indication, once one exists. The 45-day decision itself stays exactly where FDA put it: off every board a public monitoring practice, ours included, can watch.